Business
TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering
TransCode Therapeutics, Inc. (Nasdaq: RNAZ), ("TransCode" or the "Company"), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the closing of its previously announced sale of 10,250,000 shares of its common stock and warrants to purchase up to 10,250,000 shares of common stock priced at-the-market under Nasdaq rules, at a purchase price of $0.98 per share and accompanying warrant, for gross proceeds of approximately $10 million, before
About this update from Transcode Therapeutics, Inc.
[{"type":"text","content":"BOSTON, March 25, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), ("TransCode" or the "Company"), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the closing of its previously announced sale of 10,250,000 shares of its common stock and warrants to purchase up to 10,250,000 shares of common stock priced at-the-market under Nasdaq rules, at a purchase price of $0.98 per share and accompanying warrant, for gross proceeds of approximately $10 million, before deducting placement agent fees and offering expenses payable by the Company.","length":636,"tagName":"p"},{"type":"image","alt":"Logo (PRNewsfoto/TransCode Therapeutics, Inc.)","displaySize":"","headline":null,"caption":"Logo (PRNewsfoto/TransCode Therapeutics, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":58,"url":"https://media.zenfs.com/en/prnewswire.com/6158e3f623b2cdcf70a213bfe6b5eb12"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/y2kxVj5Zztrmutz6upX.Ig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEwMjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/6158e3f623b2cdcf70a213bfe6b5eb12","width":400,"height":58}},"href":"https://mma.prnewswire.com/media/2583692/TransCode_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The Company intends to use the proceeds from the offering primarily for product development activities, including one or more clinical trials with TTX-MC138, its lead therapeutic candidate, including related IND-enabling studies, and for working capital and other general corporate purposes.","length":291,"tagName":"p"},{"type":"text","content":"ThinkEquity acted as sole placement agent for the offering.","length":59,"tagName":"p"},{"type":"text","content":"The offering was made pursuant to an effective shelf registration statement that has been filed with the U.S. Securities and Exchange Commission (the "SEC"). The final prospectus supplement relating to the offering was filed with the SEC and is available on the SEC's website at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004 Attention: Prospectus Department.","length":533...